warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Novo Nordisk NN7008-3553: A Multi-centre Non-interventional Study of Safety and Efficacy of turoctocog alfa (rFVIII) during Long-Term Treatment of Severe and Moderately Severe Haemophilia A (FVIII ≤2%)
Brief Description  
The primary objective is to assess the incidence rate of FVIII inhibitors during long-term prevention and treatment of bleeds with turoctocog alfa in previously FVIII treated patients with severe and moderately severe haemophilia A.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Other Hematopoietic
Status  
OPEN
Start Date  
04/04/2017
IRB Number  
00020022
Principal Investigator  
Hinson, Ashley Rebekah Presar
Contact Name  
Gerri Robinson

For More Information, Contact  Gerri  , Robinson
Phone:  980-442-2355 Fax:    
Email:  gerri.robinson@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close